CryoPort (CYRX) Competitors $10.12 -0.59 (-5.51%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$10.24 +0.12 (+1.23%) As of 10/17/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYRX vs. COGT, GPCR, BHVN, STOK, ABCL, IMCR, VCEL, JANX, EWTX, and RCUSShould you be buying CryoPort stock or one of its competitors? The main competitors of CryoPort include Cogent Biosciences (COGT), Structure Therapeutics (GPCR), Biohaven (BHVN), Stoke Therapeutics (STOK), AbCellera Biologics (ABCL), Immunocore (IMCR), Vericel (VCEL), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. CryoPort vs. Its Competitors Cogent Biosciences Structure Therapeutics Biohaven Stoke Therapeutics AbCellera Biologics Immunocore Vericel Janux Therapeutics Edgewise Therapeutics Arcus Biosciences Cogent Biosciences (NASDAQ:COGT) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation. Is COGT or CYRX more profitable? CryoPort has a net margin of 37.21% compared to Cogent Biosciences' net margin of 0.00%. CryoPort's return on equity of -9.79% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -223.82% -89.44% CryoPort 37.21%-9.79%-5.42% Do analysts rate COGT or CYRX? Cogent Biosciences presently has a consensus target price of $19.67, indicating a potential upside of 19.99%. CryoPort has a consensus target price of $12.56, indicating a potential upside of 24.07%. Given CryoPort's stronger consensus rating and higher possible upside, analysts clearly believe CryoPort is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 1 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.71CryoPort 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 Which has more risk and volatility, COGT or CYRX? Cogent Biosciences has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Do insiders and institutionals believe in COGT or CYRX? 92.9% of CryoPort shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by insiders. Comparatively, 10.0% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor COGT or CYRX? In the previous week, Cogent Biosciences had 3 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Cogent Biosciences and 2 mentions for CryoPort. CryoPort's average media sentiment score of 0.49 beat Cogent Biosciences' score of 0.26 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, COGT or CYRX? CryoPort has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$255.86M-$1.78-9.21CryoPort$228.38M2.22-$114.76M$1.337.61 SummaryCryoPort beats Cogent Biosciences on 14 of the 16 factors compared between the two stocks. Get CryoPort News Delivered to You Automatically Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYRX vs. The Competition Export to ExcelMetricCryoPortTRANS IndustryTransportation SectorNASDAQ ExchangeMarket Cap$536.22M$5.49B$7.21B$10.50BDividend YieldN/A2.57%471.65%4.81%P/E Ratio7.6110.7315.1027.09Price / Sales2.221.16522.87210.58Price / CashN/A10.897.8661.22Price / Book1.362.922.416.52Net Income-$114.76M$183.91M$555.48M$276.75M7 Day Performance8.82%93.85%20.18%2.00%1 Month Performance0.70%-4.82%-2.03%2.26%1 Year Performance34.04%-13.18%2.88%35.58% CryoPort Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYRXCryoPort3.1695 of 5 stars$10.12-5.5%$12.56+24.1%+41.9%$536.22M$228.38M7.611,186News CoverageHigh Trading VolumeCOGTCogent Biosciences1.8709 of 5 stars$16.20-0.4%$20.00+23.5%+40.8%$1.85BN/A-9.1080News CoverageAnalyst ForecastGPCRStructure Therapeutics3.3923 of 5 stars$30.19+0.4%$68.67+127.4%-30.9%$1.73BN/A-28.75136News CoverageBHVNBiohaven3.4378 of 5 stars$15.29-3.3%$48.85+219.6%-69.0%$1.67BN/A-2.00239STOKStoke Therapeutics3.4055 of 5 stars$30.34+0.5%$27.43-9.6%+152.7%$1.65B$36.56M35.69100ABCLAbCellera Biologics2.3137 of 5 stars$5.67+2.5%$8.00+41.1%+108.6%$1.65B$28.83M-10.31500Gap UpIMCRImmunocore1.9367 of 5 stars$32.35-0.2%$56.89+75.9%-0.6%$1.63B$310.20M-80.88320VCELVericel3.3326 of 5 stars$33.49+5.1%$60.40+80.4%-13.2%$1.61B$237.22M279.11300News CoverageAnalyst UpgradeAnalyst RevisionJANXJanux Therapeutics2.3427 of 5 stars$26.29-0.8%$78.31+197.9%-46.3%$1.59B$10.59M-14.6130News CoverageEWTXEdgewise Therapeutics3.1291 of 5 stars$14.71-2.6%$38.83+164.0%-57.6%$1.59BN/A-9.4960RCUSArcus Biosciences2.3868 of 5 stars$16.64+14.0%$26.78+61.0%-9.6%$1.55B$258M-5.25500Gap Up Related Companies and Tools Related Companies Cogent Biosciences Competitors Structure Therapeutics Competitors Biohaven Competitors Stoke Therapeutics Competitors AbCellera Biologics Competitors Immunocore Competitors Vericel Competitors Janux Therapeutics Competitors Edgewise Therapeutics Competitors Arcus Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYRX) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CryoPort, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CryoPort With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYRX Stock Alerts